BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 36781872)

  • 1. Cross-protective antibodies against common endemic respiratory viruses.
    Cabán M; Rodarte JV; Bibby M; Gray MD; Taylor JJ; Pancera M; Boonyaratanakornkit J
    Nat Commun; 2023 Feb; 14(1):798. PubMed ID: 36781872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A broadly neutralizing human monoclonal antibody exhibits in vivo efficacy against both human metapneumovirus and respiratory syncytial virus.
    Schuster JE; Cox RG; Hastings AK; Boyd KL; Wadia J; Chen Z; Burton DR; Williamson RA; Williams JV
    J Infect Dis; 2015 Jan; 211(2):216-25. PubMed ID: 24864121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent cross-neutralization of respiratory syncytial virus and human metapneumovirus through a structurally conserved antibody recognition mode.
    Wen X; Suryadevara N; Kose N; Liu J; Zhan X; Handal LS; Williamson LE; Trivette A; Carnahan RH; Jardetzky TS; Crowe JE
    Cell Host Microbe; 2023 Aug; 31(8):1288-1300.e6. PubMed ID: 37516111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Respiratory Syncytial Virus and Human Metapneumovirus Infections in Three-Dimensional Human Airway Tissues Expose an Interesting Dichotomy in Viral Replication, Spread, and Inhibition by Neutralizing Antibodies.
    Kinder JT; Moncman CL; Barrett C; Jin H; Kallewaard N; Dutch RE
    J Virol; 2020 Sep; 94(20):. PubMed ID: 32759319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.
    Corti D; Bianchi S; Vanzetta F; Minola A; Perez L; Agatic G; Guarino B; Silacci C; Marcandalli J; Marsland BJ; Piralla A; Percivalle E; Sallusto F; Baldanti F; Lanzavecchia A
    Nature; 2013 Sep; 501(7467):439-43. PubMed ID: 23955151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolation and characterization of monoclonal antibodies which neutralize human metapneumovirus in vitro and in vivo.
    Ulbrandt ND; Ji H; Patel NK; Riggs JM; Brewah YA; Ready S; Donacki NE; Folliot K; Barnes AS; Senthil K; Wilson S; Chen M; Clarke L; MacPhail M; Li J; Woods RM; Coelingh K; Reed JL; McCarthy MP; Pfarr DS; Osterhaus AD; Fouchier RA; Kiener PA; Suzich JA
    J Virol; 2006 Aug; 80(16):7799-806. PubMed ID: 16873237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.
    Liang B; Kabatova B; Kabat J; Dorward DW; Liu X; Surman S; Liu X; Moseman AP; Buchholz UJ; Collins PL; Munir S
    J Virol; 2019 Apr; 93(7):. PubMed ID: 30651356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.
    Liang B; Ngwuta JO; Herbert R; Swerczek J; Dorward DW; Amaro-Carambot E; Mackow N; Kabatova B; Lingemann M; Surman S; Yang L; Chen M; Moin SM; Kumar A; McLellan JS; Kwong PD; Graham BS; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2016 Nov; 90(21):10022-10038. PubMed ID: 27581977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Pan-Pneumovirus vaccine based on immunodominant epitopes of the fusion protein.
    Huang J; Miller RJ; Mousa JJ
    Front Immunol; 2022; 13():941865. PubMed ID: 36003370
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural basis for respiratory syncytial virus and human metapneumovirus neutralization.
    Miller RJ; Mousa JJ
    Curr Opin Virol; 2023 Aug; 61():101337. PubMed ID: 37544710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates.
    Bates JT; Pickens JA; Schuster JE; Johnson M; Tollefson SJ; Williams JV; Davis NL; Johnston RE; Schultz-Darken N; Slaughter JC; Smith-House F; Crowe JE
    Vaccine; 2016 Feb; 34(7):950-6. PubMed ID: 26772634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus.
    Wen X; Mousa JJ; Bates JT; Lamb RA; Crowe JE; Jardetzky TS
    Nat Microbiol; 2017 Jan; 2():16272. PubMed ID: 28134915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.
    Liang B; Surman S; Amaro-Carambot E; Kabatova B; Mackow N; Lingemann M; Yang L; McLellan JS; Graham BS; Kwong PD; Schaap-Nutt A; Collins PL; Munir S
    J Virol; 2015 Sep; 89(18):9499-510. PubMed ID: 26157122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Potent Neutralizing Site III-Specific Human Antibody Neutralizes Human Metapneumovirus
    Bar-Peled Y; Diaz D; Pena-Briseno A; Murray J; Huang J; Tripp RA; Mousa JJ
    J Virol; 2019 Oct; 93(19):. PubMed ID: 31292250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conformational Flexibility in Respiratory Syncytial Virus G Neutralizing Epitopes.
    Fedechkin SO; George NL; Nuñez Castrejon AM; Dillen JR; Kauvar LM; DuBois RM
    J Virol; 2020 Feb; 94(6):. PubMed ID: 31852779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics and viral load of respiratory syncytial virus and human metapneumovirus in children hospitaled for acute lower respiratory tract infection.
    Yan XL; Li YN; Tang YJ; Xie ZP; Gao HC; Yang XM; Li YM; Liu LJ; Duan ZJ
    J Med Virol; 2017 Apr; 89(4):589-597. PubMed ID: 27632796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of potent RSV neutralizing antibodies isolated from human memory B cells and identification of diverse RSV/hMPV cross-neutralizing epitopes.
    Xiao X; Tang A; Cox KS; Wen Z; Callahan C; Sullivan NL; Nahas DD; Cosmi S; Galli JD; Minnier M; Verma D; Babaoglu K; Su H; Bett AJ; Vora KA; Chen Z; Zhang L
    MAbs; 2019; 11(8):1415-1427. PubMed ID: 31402751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.
    Liu X; Liang B; Ngwuta J; Liu X; Surman S; Lingemann M; Kwong PD; Graham BS; Collins PL; Munir S
    J Virol; 2017 Nov; 91(22):. PubMed ID: 28835504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant bovine/human parainfluenza virus type 3 (B/HPIV3) expressing the respiratory syncytial virus (RSV) G and F proteins can be used to achieve simultaneous mucosal immunization against RSV and HPIV3.
    Schmidt AC; McAuliffe JM; Murphy BR; Collins PL
    J Virol; 2001 May; 75(10):4594-603. PubMed ID: 11312329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of human metapneumovirus and respiratory syncytial virus WHO-defined severe pneumonia in Moroccan children.
    Jroundi I; Mahraoui C; Benmessaoud R; Moraleda C; Tligui H; Seffar M; El Kettani SE; Benjelloun BS; Chaacho S; Muñoz-Almagro C; Ruiz J; Alonso PL; Bassat Q
    Epidemiol Infect; 2016 Feb; 144(3):516-26. PubMed ID: 26143933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.